Expansion of Production Capacity and Construction of a New Manufacturing Facility
First written in FY2016. 16 of 23 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「June 2026: The ImmunoChemical Product Plant (ICPP building) at the Nogi plant was completed and production began.」
The new Nogi production building progressed from the construction and asset-recognition stage to completion of the ICPP building and the start of production. - 2026-05-12OtherEarnings presentationSuggests it is closing out
「Capital expenditures were largely completed by the previous fiscal year, and future investment will be routine investment focused mainly on maintaining and renewing these facilities.」
The company indicated that the intensive investment phase for production-capacity expansion and the new manufacturing building was largely complete, with future investment shifting mainly to maintenance and renewal. - FY2026-H1AdvancedAnnual report
「Inventories increased by ¥565 million and other current assets by ¥606 million. Tangible fixed assets increased by ¥1,653 million due to construction of the new Nogi production building and relocation of the head office, among other factors, while long-term deposits decreased by ¥1,800 million.」
Tangible fixed assets increased by ¥1,653 million due to construction of the new Nogi production building and relocation of the head office, among other factors, indicating that the facility development had progressed to the asset-recognition stage. - FY2025AdvancedAnnual report
「Major capital investment was ¥5,402 million for the new Nogi production building.」
Investment in the new Nogi production building reached ¥5,402 million, and the project had progressed to the construction and asset-recognition stage, with a total cost of ¥6,665 million and completion scheduled for June 2025. - FY2025-H1AdvancedAnnual report
「Tangible fixed assets increased by ¥3,742 million, mainly due to the recognition of construction in progress following payments for construction of the new Nogi manufacturing building.」
Recognition of construction in progress following payments for construction of the new Nogi manufacturing building progressed, increasing tangible fixed assets by ¥3,742 million. The existing plan to expand urine-testing reagent manufacturing equipment had progressed to the construction and asset-recognition stage. - FY2023-Q2AdvancedAnnual report
「Our company | Nogi site | Nogi, Tochigi Prefecture | Diagnostic reagents business | Urine-testing reagent manufacturing equipment | 570 | 183 | Internal funds | August 2022 | September 2024 | 50% increase in production capacity」
A plan was finalized to build urine-testing reagent manufacturing equipment at the Nogi site at a total cost of ¥570 million, with ¥183 million paid to date, funded with internal resources. Construction was scheduled to begin in August 2022 and be completed in September 2024, increasing production capacity by 50%. - FY2022AdvancedAnnual report
「Our company | Nogi site | New research building | 4,185 | 2,846 | Internal funds, etc. | June 2021 | August 2022」
Following the start of construction of the new research building in June 2021, the total cost was ¥4,185 million and payments made to date were ¥2,846 million. The project had progressed to the stage scheduled for completion in August 2022. - FY2022-Q3AdvancedAnnual report
「Tangible fixed assets increased by ¥2,498 million, mainly due to the recognition of construction in progress following payment of the initial deposit for construction of a new research building, while long-term deposits decreased by ¥1,100 million.」
Recognition of construction in progress following payment of the initial deposit for construction of a new research building progressed, resulting in a ¥2,498 million increase in tangible fixed assets. - FY2022-Q2AdvancedAnnual report
「Tangible fixed assets increased by ¥1,287 million, mainly due to the recognition of construction in progress following payment of the initial deposit for construction of a new research building, while long-term deposits decreased by ¥1,100 million.」
Construction in progress was recognized following payment of the initial deposit for construction of a new research building, and tangible fixed assets increased by ¥1,287 million. The construction plan had progressed to the payment and asset-recognition stage following the start of construction. - FY2021AdvancedAnnual report
「Major capital investments were ¥580 million for developing core systems, ¥523 million for novel coronavirus detection reagent production facilities, ¥1,076 million for expanding other production facilities, and ¥520 million for research and development facilities.」
The company invested ¥523 million in production facilities for novel coronavirus detection reagents and ¥1,076 million in expanding other production facilities. - FY2020RestatedAnnual report
「Major capital investments were ¥1,296 million for expanding production facilities, ¥921 million for purchasing land adjoining the Nogi site, ¥296 million for developing core systems, and ¥251 million for research and development facilities.」
The company continued investing in expanded production facilities, the purchase of land adjoining the Nogi site and research and development facilities. - FY2020-Q3AdvancedAnnual report
「The main changes included a ¥699 million increase in inventories. In addition, the company purchased land adjoining the Nogi site, increasing land by ¥971 million, while construction in progress increased by ¥363 million due to the start of preparations for redevelopment, including the adjoining land.」
The company purchased land adjoining the Nogi site and began preparations for redevelopment, including the adjoining land. Progress was reported as increases of ¥971 million in land and ¥363 million in construction in progress. - FY2020-Q2RestatedAnnual report
「The company continued preparations for redevelopment, including the area adjoining the Nogi site, and construction in progress increased by ¥434 million.」
Preparations continued for redevelopment, including the area adjoining the Nogi site, with the increase in construction in progress stated as ¥434 million. - FY2020-Q1AdvancedAnnual report
「The company began preparations for redevelopment, including the area adjoining the Nogi site, and construction in progress increased by ¥430 million.」
Preparations began for redevelopment, including the area adjoining the Nogi site, and ¥430 million was recorded as an increase in construction in progress. - FY2018RestatedAnnual report
「At the Nasu site, the company established a higher-volume production system to expand the global rollout of fecal occult blood testing reagents and LZ reagents and began operations in April 2017. At the Nogi site, it built a production line to expand production capacity for urine-testing reagents and began operations in September 2017.」
The company again reported the start of operations of the higher-volume production system at the Nasu No. 2 plant and the production line at the Nogi site. - FY2018-Q3RestatedAnnual report
「At the new manufacturing building at the Nogi site, completed in October 2016, the company built a production line to expand production capacity for urine-testing reagents and began operations in September 2017.」
It was again reported that the production line for urine-testing reagents at the new manufacturing building at the Nogi site began operations in September 2017. - FY2018-Q2AdvancedAnnual report
「At the new manufacturing building at the Nogi site, completed in October 2016, the company built a production line to expand production capacity for urine-testing reagents and began operations in September 2017.」
A production line for urine-testing reagents was built at the new manufacturing building at the Nogi site and began operations in September 2017. - FY2018-Q1AdvancedAnnual report
「During the first quarter of the current consolidated cumulative period, the following newly finalized plans for significant new facilities were established.」
A new plan was finalized to acquire land at the Nogi site for a total of ¥971 million using internal funds. The planned start date was September 2017, with completion scheduled for March 2019. - FY2017AdvancedAnnual report
「Construction of the new manufacturing building at the Nogi site to expand production capacity for urine-testing reagents and other products progressed as scheduled and was completed in October 2016. Preparations continued toward starting operation in September 2017. In addition, the Nasu No. 2 plant was expanded and refurbished to establish a higher-volume production system for expanding the global rollout of fecal occult blood testing reagents and LZ reagents. The work was completed in March 2017, and operations began in April.」
After completion of the new Nogi manufacturing building, preparations continued toward starting operation. The Nasu No. 2 plant progressed through completion in March 2017 and the start of operations in April. - FY2017-Q3RestatedAnnual report
「Construction of the new manufacturing building at the Nogi site to expand production capacity for urine-testing reagents and other products progressed as scheduled and was completed in October 2016. Preparations continued toward starting operation in September 2017. In addition, construction began on the expansion and refurbishment of the Nasu No. 2 plant to establish a higher-volume production system for expanding the global rollout of fecal occult blood testing reagents and LZ reagents, with preparations under way toward starting operation in April 2017.」
After completion of the new Nogi manufacturing building, preparations continued toward starting operation in September 2017. Preparations also continued at the Nasu No. 2 plant toward starting operation in April 2017. - FY2017-Q2AdvancedAnnual report
「Construction of the new manufacturing building at the Nogi site to expand production capacity for urine-testing reagents and other products progressed as scheduled and was completed in October 2016. Preparations for starting operation of the manufacturing equipment will continue. In addition, construction began on the expansion and refurbishment of the Nasu No. 2 plant to establish a higher-volume production system for expanding the global rollout of fecal occult blood testing reagents and LZ reagents.」
The new manufacturing building at the Nogi site was completed in October 2016, and preparations advanced toward starting operation of the manufacturing equipment. Construction also began on the expansion and refurbishment of the Nasu No. 2 plant. - FY2017-Q1AdvancedAnnual report
「Tangible fixed assets increased by ¥1,041 million, mainly due to construction of a new manufacturing building at the Nogi plant to expand production capacity.」
Construction of the new manufacturing building at the Nogi plant was under way and was recorded as an increase in tangible fixed assets. Completion was not stated. - FY2016First statedAnnual report
「During the consolidated fiscal year, the company built a new energy building at the Nogi site in June 2015 and began installing new manufacturing equipment and constructing a new manufacturing building to expand production capacity for urine-testing reagents and other products.」
Capital investment plans were presented for the Nogi and Nasu sites, including a stated 100% increase in capacity after completion of the urine-testing reagent manufacturing equipment.